U.S. RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals

By Reuters News

- Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Allstate, Autozone and Vertex Pharmaceuticals on Wednesday.


HIGHLIGHTS

* Allstate Corp ALL.N: TD Cowen raises target price to $260 from $231

* Autozone, Inc. AZO.N: D.A. Davidson cuts target price to $3,500 from $3,750

* Martin Marietta Materials, Inc. MLM.N: Jefferies cuts target price to $670 from $720

* Vertex Pharmaceuticals Inc VRTX.O: Jefferies raises target price to $640 from $633

* Vulcan Materials Co VMC.N: Jefferies cuts target price to $320 from $345

Following is a summary of research actions on U.S. companies reported by Reuters on Wednesday. Stock entries are in alphabetical order.

* Acadia Healthcare Company, Inc. ACHC.O: Leerink Partners raises PT to $33 from $30

* Allstate Corp ALL.N: TD Cowen raises target price to $260 from $231

* Amgen Inc AMGN.O: Jefferies raises target price to $410 from $367

* Anaptysbio, Inc. ANAB.O: Leerink Partners cuts target price to $81 from $90

* Anixa Biosciences Inc ANIX.O: H.C. Wainwright cuts target price to $6 from $7

* Autozone, Inc. AZO.N: D.A. Davidson cuts target price to $3,500 from $3,750

* Autozone, Inc. AZO.N: Exane BNP Paribas cuts target price to $3561 from $3979

* Autozone, Inc. AZO.N: Roth MKM cuts target price to $3850 from $4023

* Autozone, Inc. AZO.N: TD Cowen cuts target price to $3,400 from $3,500

* Bank7 Corp BSVN.O: KBW raises target price to $62 from $56

* Carnival Corp CCL.N: Jefferies cuts target price to $33 from $35

* Celldex Therapeutics Inc. CLDX.O: Leerink Partners raises target price to $88 from $70

* Compass Therapeutics Inc. CMPX.O: Guggenheim cuts target price to $4 from $8

* Compass Therapeutics Inc. CMPX.O: Jefferies cuts target price to $3 from $8

* Compass Therapeutics Inc. CMPX.O: Wedbush cuts to neutral from outperform

* Compass Therapeutics Inc. CMPX.O: Wedbush cuts target price to $1 from $5

* Cummins CMI.N: JP Morgan cuts target price to $600 from $690

* Dauch Corp DCH.N: Jefferies cuts to hold from buy; cuts target price to $7.10 from $8.25

* Graphic Packaging Holding Company GPK.N: JP Morgan raises to overweight from neutral

* Graphic Packaging Holding Company GPK.N: JP Morgan cuts target price to $11.5 from $12.5

* Guardian Pharmacy Services Inc GRDN.N: Keybanc initiates with overweight rating; PT $52

* KB Home KBH.N: Barclays cuts target price to $49 from $57

* KB Home KBH.N: RBC cuts target price to $50 from $53

* KB Home KBH.N: Truist Securities cuts target price to $50 from $55

* Martin Marietta Materials, Inc. MLM.N: Jefferies cuts target price to $670 from $720

* Marvell Technology MRVL.O: Seaport Research Partners initiates with buy rating; PT $270

* Merck & Co Inc MRK.N: TD Cowen raises target price to $155 from $137

* Onsemi ON.O: Seaport Research Partners initiates coverage with buy rating; PT $100

* Semtech Corp SMTC.O: Seaport Research Partners initiates with buy rating; target $200

* SiTime Corporation SITM.O: Seaport Research Partners initiates coverage with neutral rating

* Thor Industries, Inc. THO.N: Jefferies cuts target price to $82 from $90

* UiPath Inc PATH.N: RBC cuts target price to $15 from $17

* Vertex Pharmaceuticals Inc VRTX.O: Jefferies raises target price to $640 from $633

* Viking Therapeutics, Inc. VKTX.O: Oppenheimer raises target price to $120 from $100

* Viking Therapeutics, Inc. VKTX.O: Truist Securities raises target price to $87 from $83

* Vulcan Materials Co VMC.N: Jefferies cuts target price to $320 from $345

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.